the patient was voluntarily discharged on March 19, 2011, despite persistent hypocalcemia. After discharge, the patient gradually developed numbness and weakness of both lower limbs with subsequent dysuria. On March 30, 2011, he was admitted to the department of orthopedics at our hospital. Physical examination showed that the patient had a positive straight leg raise test in the lower extremities of both appendages, hypopselaphesia below the navel plane, and class III-V muscle strength in both lower limbs. Hypocalcemia was again identified by (page number not for citation purpose) Fig. 1 . X-ray showing pure, patchy osteosclerotic lesions of (A) distal femurs, (B) proximal tibiae, and (C) hip bones, ilium, sacrum, and proximal femurs. Bony destruction is likely evident in the right distal femur and appears to be surrounded by a patchy periosteum reaction. laboratory tests, while the hemoglobin, white blood cell count, platelet count, blood urea nitrogen, serum creatinine, aspartate aminotransferase (AST), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and albumin were all within normal ranges. The magnetic resonance imaging (MRI) revealed a tumor compressing the fifth thoracic spinal cord. An x-ray of the lungs was normal.
An open bone biopsy was performed on the bilateral distal femora and proximal tibiae, and four foci were found that exhibited mid-grade osteoblastic osteosarcoma (Fig. 4) . Based on the imaging, pathology findings, and clinical manifestation, a diagnosis of MOS was ultimately established (synchronous MOS). Following administration of neoadjuvant chemotherapy with a first cycle of methotrexate (MTX), pirarubicin (THP), and ifosfamide (IFO), the serum calcium level returned to normal, although the clinical symptoms continued to progress. A CT scan of the lung showed no signs of tumor metastases. In comparison to the previous MRI ( Fig. 5B and C), the number of lesions had increased and the tumors in the spinal canal were amplified after the neoadjuvant chemotherapy (Fig. 5A ). Due to the progression of clinical symptoms after chemotherapy, the patient's parents made the decision to discharge the patient from hospital. At the 4-month follow-up, which was conducted by telephone, we determined that the patient's symptoms had continued to deteriorate, and the patient died 15 months after diagnosis.
Discussion
Synchronous MOS is a highly aggressive variant of osteosarcoma that presents as multiple bone lesions at the time of diagnosis and usually without pulmonary metastases. This patient exhibited sufficient urinary conservation of calcium and phosphorus, as indicated by the 24 h urinary calcium and phosphorus levels ( Table 1 ). The rising level of serum parathyroid hormone (PTH) and 1, 25-dihydroxy vitamin D showed normal responses to prolonged hypocalcemia, and the patient was able to produce high levels of 1, 25-dihydroxy vitamin D despite low levels of 25-hydroxy vitamin D. The results of the BMD test showed a level 0.5% lower than that of adolescents of a similar age. Previous studies have indicated that possible explanations for low levels of 25-hydroxy vitamin D in Asian children may include increased bone formation, lower ultraviolet exposure, and insufficient dietary consumption (5, 6) . It should be noted, however, that the serum calcium level was normal in this patient upon initial assessment, and hypocalcemia rapidly developed after patient care had commenced. The serum calcium did not reach a normal level until the patient had received a complete first cycle of neoadjuvant chemotherapy. In view of the elevated PTH and ALP levels, the severe and refractory hypocalcemia in this patient was most likely caused by rapid and continued deposition of calcium by the malignant osteoblasts into the tumor osteoid (7Á9).
To date, approximately 100 cases of synchronous MOS have been reported in the literature. It remains unknown whether hypocalcaemia is associated with a poor prognosis of MOS. Hypocalcemia in patients with osteosarcoma is extremely rare, and only four cases of MOS with hypocalcemia have been reported in the literature to date (7Á10). Of these cases, one MOS patient with nonsymptomatic hypocalcemia responded to calcitriol but did not respond to i.v. and oral calcium supplementation (10), two OS patients' hypocalcemia appeared during treatment (7, 8) , and one MOS patient had obvious symptomatic hypocalcemia from the early phases of the disease (9) . Hypocalcemia in our patient first appeared during assessment and failed to respond to i.v. and oral calcium and calcitriol supplementation. The serum calcium level only became normal after aggressive neoadjuvant chemotherapy (Table 1) ; however, the clinical symptoms continued to progress (Fig. 5) . There is currently no standard of care for MOS patients, and it has been reported that all nine patients with MOS analyzed had died between 6Á17 months after diagnosis (average 12 months) (11). In summary, we have presented a rare case of synchronous MOS with hypocalcemia together with a current literature review. We conclude that it is still difficult to establish diagnosis standards for synchronous MOS, and targeted therapies should not be administered until sufficient biopsy and pathological findings are provided, since synchronous MOS has a similar presentation as metabolic bone diseases and significant clinical improvements from these therapies have not been achieved. Importantly, we suspect that hypocalcemia during MOS may be associated with the disease progression and poor prognosis. Further investigations are needed to explore these possibilities. Hypocalcaemia could be a manifestation of this condition and therefore the clinician should be aware of this possibility.
